Filing identity and reporting period
The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2015, filed February 4, 2016. This does not match the request metadata identifying Lite Strategy, Inc. and 2014 Q2; verify the issuer and period before relying on this summary.
MEI Pharma is a clinical-stage oncology company listed on Nasdaq as MEIP. It reported no revenue and is developing Pracinostat, ME-401, and ME-344.
Key financial metrics
Dollar amounts below are in millions unless noted. The filing presents expenses and losses as negative amounts.
| Metric | Three months ended Dec. 31, 2015 | Three months ended Dec. 31, 2014 | Six months ended Dec. 31, 2015 | Six months ended Dec. 31, 2014 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $3.182 | $6.703 | $5.998 | $13.269 |
| General and administrative expense | $1.945 | $2.415 | $3.775 | $4.854 |
| Total operating expenses | $5.127 | $9.118 | $9.773 | $18.123 |
| Net loss | $5.101 | $9.109 | $9.721 | $18.102 |
| Basic and diluted loss per share | $0.15 | $0.39 | $0.28 | $0.80 |
| Cash used in operations | Not provided for quarter | Not provided for quarter | $9.989 | $13.179 |
- At December 31, 2015, cash and cash equivalents were $13.674 million and short-term investments were $40.116 million, totaling $53.790 million, versus $63.779 million at June 30, 2015.
- Total assets were $55.016 million; current liabilities were $3.378 million; stockholders’ equity was $51.638 million. The filing reports no debt balance.
- For the six months, investing activities provided $4.941 million, mainly because investment maturities exceeded purchases. Financing activities provided no cash; the prior-year period included $43.104 million net proceeds from an equity offering.
- Margins are not meaningful because the company reported no revenue.
Changes versus prior comparable periods
- Quarterly net loss declined to $5.1 million from $9.1 million; six-month net loss declined to $9.7 million from $18.1 million.
- R&D expense fell by $3.5 million for the quarter and $7.3 million for the six months. Management attributed the decreases mainly to lower Pracinostat trial and manufacturing costs, and, for the six-month period, lower ME-344 trial costs as well.
- G&A expense fell by $0.5 million for the quarter and $1.1 million for the six months, primarily due to lower share-based compensation.
- Six-month operating cash use improved to $10.0 million from $13.2 million. Cash and cash equivalents decreased by $5.048 million during the six months ended December 31, 2015.
Outlook, risks, and contingencies
- Management said existing cash, cash equivalents, and investments were expected to fund operations through at least fiscal 2017. It expects operating losses and negative operating cash flows to continue and anticipates seeking future financing or strategic partnerships.
- Planned studies, as stated in the filing, included a Phase III registration-oriented Pracinostat study in elderly newly diagnosed AML patients in the second half of calendar 2016; a Phase Ib ME-401 study in recurrent CLL or follicular lymphoma in the second quarter of 2016; and an investigator-sponsored ME-344 study with bevacizumab in HER2-negative breast cancer in the second quarter of 2016. These were expectations, not completed milestones.
- Pracinostat plus azacitidine failed to improve the primary endpoint in a Phase II MDS study. The company said it would prioritize further development in AML; reported AML study results included a 56% CR/CRi/morphologic leukemia-free state response rate in 50 patients, but these were clinical-study findings and not evidence of approval.
- ME-344 combined with topotecan showed insufficient activity to warrant further development. The filing also describes clinical-development, regulatory, financing, manufacturing, competition, and intellectual-property risks.
- Potential S*Bio milestone and earnout payments could total up to $75.2 million subject to specified regulatory and sales milestones. The first stated milestone includes $200,000 plus $500,000 in company shares upon first patient dosing in a Phase III or other pivotal trial. The company had accrued $250,000 for potential future payments as of December 31, 2015.
- The office lease was due to expire in June 2016, with $161,000 of future minimum payments reported. The shelf registration statement had $104 million of securities remaining, but the company’s public float was below $75 million, limiting sales under the shelf to one-third of non-affiliate public-float market value in any 12-month period. No shelf shares were sold in calendar 2015.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting. The filing reported no legal proceedings and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm that MEI Pharma and the quarter ended December 31, 2015 are the intended issuer and period, given the conflicting request metadata.
- Check subsequent filings for actual cash runway, financing activity, and whether planned clinical trials began on schedule.
- Review clinical-trial updates, especially the limitations of the small AML study and the failed MDS primary endpoint.
- Assess potential dilution from future equity financing, outstanding warrants, and stock-based compensation; the filing excluded 6,595,970 potentially dilutive securities from diluted loss per share as antidilutive.
- Review the terms and triggering conditions for S*Bio milestone obligations and other clinical, licensing, and employment commitments.